1. Home
  2. MIRM vs SNX Comparison

MIRM vs SNX Comparison

Compare MIRM & SNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MIRM
  • SNX
  • Stock Information
  • Founded
  • MIRM 2018
  • SNX 1980
  • Country
  • MIRM United States
  • SNX United States
  • Employees
  • MIRM N/A
  • SNX N/A
  • Industry
  • MIRM Biotechnology: Pharmaceutical Preparations
  • SNX Retail: Computer Software & Peripheral Equipment
  • Sector
  • MIRM Health Care
  • SNX Technology
  • Exchange
  • MIRM Nasdaq
  • SNX Nasdaq
  • Market Cap
  • MIRM 2.5B
  • SNX 11.2B
  • IPO Year
  • MIRM 2019
  • SNX 2003
  • Fundamental
  • Price
  • MIRM $52.66
  • SNX $141.09
  • Analyst Decision
  • MIRM Strong Buy
  • SNX Strong Buy
  • Analyst Count
  • MIRM 9
  • SNX 9
  • Target Price
  • MIRM $66.22
  • SNX $140.89
  • AVG Volume (30 Days)
  • MIRM 456.2K
  • SNX 1.1M
  • Earning Date
  • MIRM 08-06-2025
  • SNX 06-24-2025
  • Dividend Yield
  • MIRM N/A
  • SNX 1.24%
  • EPS Growth
  • MIRM N/A
  • SNX 19.95
  • EPS
  • MIRM N/A
  • SNX 8.55
  • Revenue
  • MIRM $379,251,000.00
  • SNX $60,007,297,000.00
  • Revenue This Year
  • MIRM $35.83
  • SNX $4.63
  • Revenue Next Year
  • MIRM $16.83
  • SNX $4.23
  • P/E Ratio
  • MIRM N/A
  • SNX $16.57
  • Revenue Growth
  • MIRM 69.31
  • SNX 6.60
  • 52 Week Low
  • MIRM $36.17
  • SNX $92.23
  • 52 Week High
  • MIRM $54.23
  • SNX $145.10
  • Technical
  • Relative Strength Index (RSI)
  • MIRM 64.66
  • SNX 70.28
  • Support Level
  • MIRM $49.22
  • SNX $138.25
  • Resistance Level
  • MIRM $53.86
  • SNX $144.17
  • Average True Range (ATR)
  • MIRM 1.57
  • SNX 3.59
  • MACD
  • MIRM 0.08
  • SNX 0.39
  • Stochastic Oscillator
  • MIRM 79.63
  • SNX 84.85

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About SNX TD SYNNEX Corporation

TD Synnex Corp is a distributor and solutions aggregator for the IT ecosystem. The company aggregates and distributes IT hardware, software, and systems including personal computing devices and peripherals, mobile phones and accessories, printers, server and data center infrastructure, hybrid cloud, security, networking, communications and storage solutions, and system components. Its geographical segments include the Americas, Europe, and APJ.

Share on Social Networks: